CoChat

Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta‐analysis

Luchini, Claudio, Veronese, Nicola, Yachida, Shinichi, Cheng, Liang, Nottegar, Alessia, Stubbs, Brendon, Solmi, Marco, Capelli, Paola, Pea, Antonio, Barbareschi, Mattia, Fassan, Matteo, Wood, Laura D, Scarpa, Aldo · 2016 · Genes, Chromosomes and Cancer
Cited by 62

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Biallelic inactivation of the tumor suppressor gene BRCA1‐associated protein 1 (BAP1) has been demonstrated in several cancers, but its prognostic role has not been completely explained. We aimed to investigate the risk associated with loss of BAP1 (BAP1‐) for all‐cause mortality, cancer‐specific mortality and recurrence of disease in subjects with cancer. PubMed and SCOPUS were searched from database inception until 09/15/2015 without language restrictions. Prospective studies reporting data on prognostic parameters in subjects with cancer, comparing participants with presence of BAP1 (BAP1+) vs. BAP1‐ were included. Data were summarized using risk ratios (RR) for number of deaths/recurrences and hazard ratios (HR) for time‐dependent risk related to BAP1‐ adjusted for potential confounders. From 261 hits, 12 studies (including 13 cohorts) with 3,447 participants (BAP1‐: n = 697; BAP1+: n = 2,750), with a median follow‐up over 60 months, were meta‐analyzed. Compared to BAP1+, BAP1‐ significantly increased all‐cause mortality, cancer‐specific mortality and risk of recurrence in all the tumor types analyzed, except for mesothelioma, in which the presence of BAP1 mutations correlates with a better prognosis. Furthermore, we demonstrated that BAP1 mutated colorectal and renal carcinomas are associated with high‐tumor grading (P < 0.0001), and that BAP1 mutated is more common in women than in men (P < 0.0001). In conclusion, on the basis of our meta‐analysis, we have demonstrated a peculiar role of BAP1 in influencing the prognosis in cancer. Thus, BAP1 could be considered as an important potential target for personalized medicine. © 2016 Wiley Periodicals, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/gcc.22381

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Luchini, C., Veronese, N., Yachida, S., Cheng, L., Nottegar, A., Stubbs, B., Solmi, M., Capelli, P., Pea, A., Barbareschi, M., Fassan, M., Wood, L. D., & Scarpa, A.
Venue
Genes, Chromosomes and Cancer
Publisher
Wiley
Published
2016-07-07
Volume
55
Issue
10
Pages
741-749
ISSN
  • 1045-2257 (ISSN-L)
  • 1098-2264
OpenAlex
W2398261979
Cited by
62
References
2
FWCI
0.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.